^
Association details:
| Biomarker: | PD-L1 expression + EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | PD-L1 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Acquired resistance to PD-1 blockade in NSCLC.
Published date:
05/13/2020
Excerpt:
We retrospectively collected data for patients with unresectable stage III NSCLC harboring EGFR mutations...All patients with NSCLC treated with PD-1 blockade at MSKCC were examined….Patients with PD-L1 expression < 50% and TMB < 8mut/Mb were more likely to develop resistance compared those with PD-L1 expression ≥50% and TMB ≥8mut/Mb (OR 5.5, p = 0.02).
DOI:
10.1200/JCO.2020.38.15_suppl.9621
